Stock 7775 DAIKEN MEDICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daiken Medical Co., Ltd.

Equities

7775

JP3482500000

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange
Other stock markets
 07:00:00 27/06/2024 BST 		5-day change 1st Jan Change
543 JPY -0.18% Intraday chart for Daiken Medical Co., Ltd. +1.88% +5.85%
05-15 Daiken Medical Co., Ltd. Provides Non-Consolidated Earnings Forecast for the Six Months Ending September 30, 2024 and Full Year Ending March 31, 2025 CI
05-15 Daiken Medical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2025; Declares Cash Dividend for the Year Ended March 31, 2024, Payable on June 3, 2024 CI

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 18,875 17,496 14,652 13,818 15,944 15,600 - -
Enterprise Value (EV) 1 19,426 18,279 15,067 14,057 15,347 15,600 15,600 15,600
P/E ratio 22 x 25.9 x 17.6 x 19.4 x 16.1 x 15.1 x 12.6 x 11 x
Yield 3.04% 3.28% 3.92% 4.16% 3.78% 4.05% 4.33% 4.6%
Capitalization / Revenue 2.21 x 2.23 x 1.72 x 1.51 x 1.64 x 1.53 x 1.42 x 1.31 x
EV / Revenue 2.21 x 2.23 x 1.72 x 1.51 x 1.64 x 1.53 x 1.42 x 1.31 x
EV / EBITDA 13 x 14.9 x 10 x 10.5 x 9.62 x 8.43 x 6.93 x 5.89 x
EV / FCF 14.8 x - 15.7 x 17.5 x - 16.1 x 16.6 x 15.4 x
FCF Yield 6.75% - 6.35% 5.72% - 6.22% 6.03% 6.47%
Price to Book 3.1 x 2.83 x 2.28 x 2.1 x 2.28 x 2.08 x 1.91 x 1.72 x
Nbr of stocks (in thousands) 28,728 28,728 28,728 28,728 28,728 28,728 - -
Reference price 2 657.0 609.0 510.0 481.0 555.0 543.0 543.0 543.0
Announcement Date 15/05/20 14/05/21 13/05/22 15/05/23 15/05/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 8,523 7,862 8,540 9,137 9,750 10,200 11,000 11,900
EBITDA 1 1,448 1,178 1,465 1,321 1,657 1,850 2,250 2,650
EBIT 1 1,194 921.2 1,150 1,054 1,442 1,600 1,900 2,200
Operating Margin 14.01% 11.72% 13.47% 11.54% 14.79% 15.69% 17.27% 18.49%
Earnings before Tax (EBT) 1 1,191 944.8 1,151 1,025 1,436 1,600 1,900 2,300
Net income 1 859 675.2 831 712 988 1,090 1,300 1,485
Net margin 10.08% 8.59% 9.73% 7.79% 10.13% 10.69% 11.82% 12.48%
EPS 2 29.92 23.50 28.93 24.79 34.41 36.05 43.05 49.35
Free Cash Flow 1 1,275 - 930.4 790.1 - 971 940 1,010
FCF margin 14.96% - 10.89% 8.65% - 9.52% 8.55% 8.49%
FCF Conversion (EBITDA) 88.05% - 63.5% 59.8% - 52.49% 41.78% 38.11%
FCF Conversion (Net income) 148.39% - 111.96% 110.97% - 89.08% 72.31% 68.01%
Dividend per Share 2 20.00 20.00 20.00 20.00 21.00 22.00 23.50 25.00
Announcement Date 15/05/20 14/05/21 13/05/22 15/05/23 15/05/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S2 2021 S1 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2025 S2
Net sales 1 4,275 3,771 4,086 2,334 2,120 4,454 2,196 2,258 4,454 2,442 2,241 4,683 2,361 2,463 4,824 2,582 2,344 4,926 2,440 2,560 5,000 2,710 2,590 5,300
EBITDA - - - - - - - - - - - - - - - - - - - - - - - -
EBIT 1 629 452 565 368 217 585 288 317 605 364 85 449 339 406 745 492 205 697 340 420 760 490 350 840
Operating Margin 14.71% 11.99% 13.83% 15.77% 10.24% 13.13% 13.11% 14.04% 13.58% 14.91% 3.79% 9.59% 14.36% 16.48% 15.44% 19.05% 8.75% 14.15% 13.93% 16.41% 15.2% 18.08% 13.51% 15.85%
Earnings before Tax (EBT) 1 612 488 564 368 219 587 288 316 604 364 57 421 341 409 750 487 199 686 340 420 760 490 350 840
Net income 1 445 350 400 262 169 431 202 227 429 259 24 283 244 293 537 351 100 451 250 250 500 380 200 580
Net margin 10.41% 9.28% 9.79% 11.23% 7.97% 9.68% 9.2% 10.05% 9.63% 10.61% 1.07% 6.04% 10.33% 11.9% 11.13% 13.59% 4.27% 9.16% 10.25% 9.77% 10% 14.02% 7.72% 10.94%
EPS - 12.20 13.93 9.120 - - 7.040 - 14.94 9.010 - - 8.520 - 18.72 12.20 - - - - - - - -
Dividend per Share - 9.000 9.000 - - - - - 9.000 - - - - - 9.000 - - - - - - - - -
Announcement Date 15/05/20 30/10/20 29/10/21 31/01/22 13/05/22 13/05/22 29/07/22 31/10/22 31/10/22 31/01/23 15/05/23 15/05/23 31/07/23 31/10/23 31/10/23 31/01/24 15/05/24 15/05/24 - - - - - -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 551 783 415 239 - - - -
Net Cash position - - - - 597 - - -
Leverage (Debt/EBITDA) 0.3806 x 0.6648 x 0.2832 x 0.1809 x - - - -
Free Cash Flow 1 1,275 - 930 790 - 971 940 1,010
ROE (net income / shareholders' equity) 14.5% 11% 13.2% 10.9% 14.6% 15% 16.7% 18.4%
ROA (Net income/ Total Assets) 11% 8.8% 10.6% 9.6% 13.2% 13.9% 15.3% 17.3%
Assets 1 7,797 7,673 7,817 7,415 7,502 7,842 8,497 8,584
Book Value Per Share 2 212.0 215.0 224.0 229.0 243.0 261.0 284.0 315.0
Cash Flow per Share 38.70 32.40 39.90 34.10 41.80 - - -
Capex 1 162 312 203 227 162 200 450 450
Capex / Sales 1.9% 3.97% 2.38% 2.48% 1.66% 1.96% 4.09% 3.78%
Announcement Date 15/05/20 14/05/21 13/05/22 15/05/23 15/05/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Daiken Medical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

1st Jan change Capi.
DAIKEN MEDICAL CO., LTD. Stock Daiken Medical Co., Ltd.
+5.85% 97.26M
SHOCKWAVE MEDICAL Stock Shockwave Medical
+75.69% 12.57B
MASIMO CORPORATION Stock Masimo Corporation
+12.19% 7B
PENUMBRA, INC. Stock Penumbra, Inc.
-30.47% 6.78B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+9.17% 5.2B
GETINGE AB Stock Getinge AB
-20.22% 4.67B
APT MEDICAL INC. Stock APT Medical Inc.
+16.71% 4.26B
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.04% 3.84B
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-27.62% 2.7B
SKAN GROUP AG Stock SKAN Group AG
-0.99% 1.98B
Medical Equipment
  1. Stock Market
  2. Equities
  3. 7775 Stock
  4. Financials Daiken Medical Co., Ltd.